Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$15.08 USD
+0.20 (1.34%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $15.07 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth A Momentum A VGM
Income Statements
Fiscal Year end for Takeda Pharmaceutical Co falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | 29,420 | 29,803 | 31,764 | 30,059 | 30,279 |
Cost Of Goods | 9,844 | 9,206 | 9,851 | -9,347 | 10,026 |
Gross Profit | 19,576 | 20,597 | 21,913 | 39,406 | 20,253 |
Selling & Adminstrative & Depr. & Amort Expenses | 18,099 | 16,967 | 17,812 | 15,926 | 19,329 |
Income After Depreciation & Amortization | 1,477 | 3,630 | 4,102 | 23,480 | 924 |
Non-Operating Income | 404 | 402 | 74 | 993 | 35 |
Interest Expense | 1,517 | 1,256 | 1,483 | 2,337 | 1,518 |
Pretax Income | 364 | 2,776 | 2,693 | 3,443 | -559 |
Income Taxes | -631 | 430 | 644 | -93 | -966 |
Minority Interest | 1 | 0 | 1 | 2 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 995 | 2,346 | 2,048 | 3,536 | 407 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 994 | 2,346 | 2,048 | 3,534 | 407 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 6,500 | 8,546 | 9,292 | 28,741 | 6,293 |
Depreciation & Amortization (Cash Flow) | 5,023 | 4,917 | 5,190 | 5,261 | 5,370 |
Income After Depreciation & Amortization | 1,477 | 3,630 | 4,102 | 23,480 | 924 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | 3,124.59 | 3,103.60 | 3,154.30 | 3,147.01 | 3,114.41 |
Diluted EPS Before Non-Recurring Items | 1.67 | 2.07 | 1.89 | 1.98 | 1.78 |
Diluted Net EPS (GAAP) | 0.31 | 0.75 | 0.65 | 1.12 | 0.13 |
Fiscal Year end for Takeda Pharmaceutical Co falls in the month of March .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 7,731.14 | 6,938.67 | 7,556.07 | 7,197.31 | 7,727.91 |
Cost Of Goods | 2,476.51 | 2,548.76 | 2,580.47 | 2,370.72 | 2,344.13 |
Gross Profit | 5,254.63 | 4,389.91 | 4,975.59 | 4,826.60 | 5,383.78 |
SG&A, R&D, and Dept/Amort Expenses | 4,190.13 | 4,516.31 | 4,262.18 | 5,167.06 | 4,153.21 |
Income After SG&A, R&D, and Dept/Amort Expenses | 1,064.50 | -126.40 | 713.41 | -340.46 | 1,230.57 |
Non-Operating Income | 191.78 | -25.50 | 160.99 | 78.55 | 190.07 |
Interest Expense | 382.02 | 223.88 | 457.84 | 400.35 | 434.90 |
Pretax Income | 874.27 | -375.79 | 416.57 | -662.26 | 985.74 |
Income Taxes | 264.35 | -329.94 | -302.57 | -331.26 | 333.08 |
Minority Interest | 0.33 | 0.16 | 0.24 | 0.41 | 0.08 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 609.92 | -45.85 | 719.14 | -331.00 | 652.66 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 609.59 | -46.01 | 718.90 | -331.41 | 652.58 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 3,138.00 | 3,033.33 | 3,161.48 | 3,112.00 | 3,130.08 |
Diluted EPS Before Non-Recurring Items | 0.56 | 0.00 | 0.51 | 0.50 | 0.55 |
Diluted Net EPS (GAAP) | 0.19 | -0.01 | 0.23 | -0.11 | 0.21 |